Key Highlights
- Quantum-Si furnished slides presented at World HUPO 2026 in Singapore on its next-generation protein sequencing platform, Proteus.
- The Proteus nanowell array has an estimated 80 million wells, compared with 2 million on the current Platinum Pro.
- Interim data show a median false discovery rate of 1.36% against 6.58% for Platinum Pro, a 4.8-fold improvement.
- Launch is targeted for the second quarter of 2027, contingent on system integration and validation work.
Quantum-Si Incorporated (NASDAQ:QSI) used a Form 8-K to put its next-generation protein sequencing platform, Proteus, in front of investors. The company furnished the slides it presented at World HUPO 2026 in Singapore, along with a press release, stating that the Proteus nanowell array has an estimated 80 million wells compared with 2 million on its current Platinum Pro instrument and that launch is targeted for the second quarter of 2027.
The report was filed September 29, 2026 and describes the Singapore presentation as taking place on September 28, 2026.
What the Presentation Says
The slides, filed as Exhibit 99.1, describe Proteus as a benchtop instrument with an imaging system and an automated workflow, in contrast to the more manual approach of Platinum Pro. The instrument measures 17.8 inches wide, 27.1 inches tall and 27.3 inches deep. The consumable uses a nanowell array with an estimated 80 million wells at launch, which the presentation puts at 40 times the capacity of Platinum Pro's 2 million wells. The company describes three uses for the added capacity: more samples in a run, deeper analysis of a single sample for rare events, and multiplexing for cost-sensitive applications.
Interim Data Against Platinum Pro
The presentation compares interim Proteus data with Platinum Pro. It reports roughly 60 times more alignments per full instrument run, a median false discovery rate of 1.36% against 6.58% for Platinum, which it calls a 4.8-fold improvement, and 1.6 to 2.0 times as many peptides identified in single-chamber runs. It also reports 4.3 times greater amino acid coverage in protein mixtures.
Development Milestones and Caveats
The presentation says Proteus currently detects 18 amino acids and that the company aims to "Continue to expand amino acid coverage and demonstrate detection of all 20 AAs by end of 2026." It anticipates AI-based algorithms for reference-free sequencing and detection of post-translational modifications in 2027. The Q2 2027 launch target is described as contingent on completing system integration and validation activities.
The slides carry a substantial forward-looking statements notice acknowledging that "actual results of the Company may differ from its expectations," and it cites risks including technical challenges, regulatory uncertainty and competition. One line stands out for its plainness: "Proteus instrument, consumables, loading protocol and analysis software are in development and will continue to be improved." In other words, the specifications and results shown are not those of a finished commercial product.
The 8-K is filed under Item 7.01, Regulation FD Disclosure, and includes the standard statement that the information is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. Exhibit 99.2 is a press release dated September 28, 2026. Quantum-Si is a Delaware corporation located at 29 Business Park Drive in Branford, Connecticut, and its shares trade on Nasdaq as QSI. Chief Financial Officer Jeffry Keyes signed the report.
Quantum-Si's Proteus Milestones Through 2027
The dates to follow are the ones in the presentation: the goal of demonstrating detection of all 20 amino acids by the end of 2026, the expected launch in the second quarter of 2027, and the algorithm work anticipated for 2027. The company's periodic reports and future 8-Ks are where any change to those timetables, or to the assumptions behind them, would appear.






Please wait processing your request...